Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2013 ASCO Annual Meeting

30 May - 3 Jun 2013
McCormick Place, Chicago, United States of America
Role of microenvironment and stroma in cancer therapy
Dr Stephen Ansell - Mayo Clinic, Rochester, USA
Role of microenvironment and stroma in cancer therapy ( Dr Stephen Ansell - Mayo Clinic, Rochester, USA )
7 Jun 2013
Latest on metastatic castration resistant prostate cancer from ASCO 2013
Professor Maria De Santis, Dr Kurt Miller, Dr Dana Rathkopf and Dr Charles Ryan
Latest on metastatic castration resistant prostate cancer from ASCO 2013 ( Professor Maria De Santis, Dr Kurt Miller, Dr Dana Rathkopf and Dr Charles Ryan )
7 Jun 2013
Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives ...
Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives no survival benefit ( Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
6 Jun 2013
Science behind phase I clinical trials: targeting tumour cell development pathwa...
Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
Science behind phase I clinical trials: targeting tumour cell development pathways ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013
ASCO 2013 highlights
Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
ASCO 2013 highlights ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013
Crizotinib superior to chemo for advanced ALK positive NSCLC
Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Crizotinib superior to chemo for advanced ALK positive NSCLC ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
6 Jun 2013
Next generation of anti-cancer agents: data from ASCO 2013
Dr Sarah Blagden - Imperial College, London, UK
Next generation of anti-cancer agents: data from ASCO 2013 ( Dr Sarah Blagden - Imperial College, London, UK )
4 Jun 2013
Phase I study measures effect of ipilimumab and nivolumab combination in melanom...
Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA
Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients ( Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )
3 Jun 2013
Axillary radiotherapy provides alternative to invasive early stage breast cancer...
Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam
Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery ( Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam )
3 Jun 2013
Comment on progression free survival in lung cancer patients and the GALAXY-1 tr...
Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA
Comment on progression free survival in lung cancer patients and the GALAXY-1 trial ( Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA )
3 Jun 2013
Paclitaxel dosing equally effective in preventing breast cancer progression
Dr Andrew Seidman - Memorial Sloan-Kettering Cancer Center, New York, USA
Paclitaxel dosing equally effective in preventing breast cancer progression ( Dr Andrew Seidman - Memorial Sloan-Kettering Cancer Center, New York, USA )
3 Jun 2013
Biennial cervical cancer screening with vinegar reduces mortality
Dr Surendra Srinivas Shastri - Tata Memorial Hospital Mumbai, India
Biennial cervical cancer screening with vinegar reduces mortality ( Dr Surendra Srinivas Shastri - Tata Memorial Hospital Mumbai, India )
3 Jun 2013
Paclitaxel chemotherapy schedules equally effective for early-stage breast cance...
Dr G. Thomas Budd - Cleveland Clinic, Cleveland, USA
Paclitaxel chemotherapy schedules equally effective for early-stage breast cancer ( Dr G. Thomas Budd - Cleveland Clinic, Cleveland, USA )
3 Jun 2013
Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer
Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Ganetespib inhibits Hsp90 with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
3 Jun 2013
Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab
Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
3 Jun 2013
Nivolumab blocking PD1 in lung cancer and melanoma
Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA
Nivolumab blocking PD1 in lung cancer and melanoma ( Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA )
3 Jun 2013
Crizotinib and molecular testing in advanced non small cell lung cancer
Dr Fred Hirsch - University of Colorado, Denver, USA
Crizotinib and molecular testing in advanced non small cell lung cancer ( Dr Fred Hirsch - University of Colorado, Denver, USA )
3 Jun 2013
Nintedanib in combination with standard second line therapy in lung cancer
Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany
Nintedanib in combination with standard second line therapy in lung cancer ( Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany )
3 Jun 2013
The problem of unnecessary treatment of prostate cancer
Dr Rosalind Eeles - Royal Marsden Hospital, London, UK
The problem of unnecessary treatment of prostate cancer ( Dr Rosalind Eeles - Royal Marsden Hospital, London, UK )
3 Jun 2013
Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for ad...
Dr Suresh S. Ramalingam - Emory University, Atlanta, USA
Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )
3 Jun 2013
One in five african american women with breast cancer carry inherited mutations
Dr Jane E. Churpek - University of Chicago, USA
One in five african american women with breast cancer carry inherited mutations ( Dr Jane E. Churpek - University of Chicago, USA )
3 Jun 2013
Axillary radiotherapy provides alternative to invasive early stage breast cancer...
Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam
Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery ( Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam )
3 Jun 2013
Paclitaxel chemotherapy schedules are equally effective for early-stage breast c...
Dr G. Thomas Budd - MD Cleveland Clinic, USA
Paclitaxel chemotherapy schedules are equally effective for early-stage breast cancer ( Dr G. Thomas Budd - MD Cleveland Clinic, USA )
3 Jun 2013
Surveys reveal shortages of common cancer drugs are ongoing
Dr Keerthi Gogineni - University of Pennsylvania, Philadelphia, USA
Surveys reveal shortages of common cancer drugs are ongoing ( Dr Keerthi Gogineni - University of Pennsylvania, Philadelphia, USA )
3 Jun 2013
Selumetinib, the first effective drug for advanced melanoma of the eye
Dr Richard Carvajal - Memorial Sloan Kettering Cancer Center, New York, USA
Selumetinib, the first effective drug for advanced melanoma of the eye ( Dr Richard Carvajal - Memorial Sloan Kettering Cancer Center, New York, USA )
3 Jun 2013
Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer
Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA
Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer ( Dr Marcia Brose - University of Pennsylvania, Philadelphia, USA )
2 Jun 2013
Extended use of tamoxifen reduces breast cancer recurrence and death
Prof Richard Gray - University of Oxford, Oxford, United Kingdom
Extended use of tamoxifen reduces breast cancer recurrence and death ( Prof Richard Gray - University of Oxford, Oxford, United Kingdom )
2 Jun 2013
Ipilimumab and BRAF inhibitors for advanced melanoma
Dr Lynn Schuchter - University of Pennsylvania, USA
Ipilimumab and BRAF inhibitors for advanced melanoma ( Dr Lynn Schuchter - University of Pennsylvania, USA )
2 Jun 2013
Effect of metformin on cancer risk and mortality
Dr Sara Gandini - European Institute of Oncology (IEO), Milan, Italy
Effect of metformin on cancer risk and mortality ( Dr Sara Gandini - European Institute of Oncology (IEO), Milan, Italy )
2 Jun 2013
PDL1 inhibitors in melanoma
Dr Roy Herbst - Yale Cancer Center, New Haven, USA
PDL1 inhibitors in melanoma ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )
2 Jun 2013
Ten years of tamoxifen superior to five in reducing breast cancer recurrence and...
Dr Richard G. Gray - University of Oxford, UK
Ten years of tamoxifen superior to five in reducing breast cancer recurrence and death ( Dr Richard G. Gray - University of Oxford, UK )
2 Jun 2013
Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer
Dr Marcia Brose - Abramson Cancer Center, University of Pennsylvania, USA
Sorafenib stalls growth of treatment-resistant differentiated thyroid cancer ( Dr Marcia Brose - Abramson Cancer Center, University of Pennsylvania, USA )
2 Jun 2013
No survival benefit to adding bevacizumab to standard first-line chemoradiation ...
Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma ( Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
2 Jun 2013
Bevacizumab extends survival for relapsed and advanced cervical cancer
Dr Krishnansu Sujata Tewari - University of California Irvine Medical Center, US...
Bevacizumab extends survival for relapsed and advanced cervical cancer ( Dr Krishnansu Sujata Tewari - University of California Irvine Medical Center, USA )
2 Jun 2013
Biennial cervical cancer screening with vinegar reduces mortality
Dr Surendra Srinivas Shastri - Tata Memorial Hospital Mumbai, India
Biennial cervical cancer screening with vinegar reduces mortality ( Dr Surendra Srinivas Shastri - Tata Memorial Hospital Mumbai, India )
2 Jun 2013
Comment on drug developments in advanced melanoma
Dr Roy Herbst - Yale Cancer Center, New Haven, USA
Comment on drug developments in advanced melanoma ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )
2 Jun 2013
Brentuximab vedotin in the frontline setting
Dr Stephen Ansell - Mayo Clinic, Rochester, USA
Brentuximab vedotin in the frontline setting ( Dr Stephen Ansell - Mayo Clinic, Rochester, USA )
2 Jun 2013
Comment on biennial visual inspection with acetic acid (VIA), or vinegar
Prof Krishnansu Sujata Tewari - University of California Irvine, Orange, USA
Comment on biennial visual inspection with acetic acid (VIA), or vinegar ( Prof Krishnansu Sujata Tewari - University of California Irvine, Orange, USA )
2 Jun 2013
Effects of The Cancer Genome Atlas
Dr Matthew Ellis - Washington University in St Louis, USA
Effects of The Cancer Genome Atlas ( Dr Matthew Ellis - Washington University in St Louis, USA )
2 Jun 2013
AMAROS trial: radiotherapy versus lymph node dissection in breast cancer
Dr Robert Mansel - Cardiff University, UK
AMAROS trial: radiotherapy versus lymph node dissection in breast cancer ( Dr Robert Mansel - Cardiff University, UK )
2 Jun 2013
Lapatinib in combination with chemotherapy in breast cancer
Dr J. Randolph Hecht - UCLA Medical Center, Santa Monica, USA
Lapatinib in combination with chemotherapy in breast cancer ( Dr J. Randolph Hecht - UCLA Medical Center, Santa Monica, USA )
2 Jun 2013
Cetuximab superior to bevacizumab for advanced colorectal cancer
Dr Volke Heinemann - University of Munich Munich, Germany
Cetuximab superior to bevacizumab for advanced colorectal cancer ( Dr Volke Heinemann - University of Munich Munich, Germany )
1 Jun 2013
Improving outcomes of childhood neuroblastoma
Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, U...
Improving outcomes of childhood neuroblastoma ( Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, USA )
1 Jun 2013
Nivolumab produces long-lasting responses in patients with stage IV melanoma
Dr Mario Sznol - Yale Cancer Center, New Haven, USA
Nivolumab produces long-lasting responses in patients with stage IV melanoma ( Dr Mario Sznol - Yale Cancer Center, New Haven, USA )
1 Jun 2013
Delayed relapse of advanced ovarian cancer when treating with pazopanib
Dr Andreas du Bois - Kliniken Essen Mitte, Essen, Germany
Delayed relapse of advanced ovarian cancer when treating with pazopanib ( Dr Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )
1 Jun 2013
Cetuximab superior to bevacizumab for advanced colorectal cancer
Dr Volker Heinemann - University of Munich, Germany
Cetuximab superior to bevacizumab for advanced colorectal cancer ( Dr Volker Heinemann - University of Munich, Germany )
1 Jun 2013
Spouses of patients with HPV-positive oropharyngeal cancer do not have increased...
Dr Gypsyamber D’Souza - Johns Hopkins Bloomberg School of Public Health, Baltimo...
Spouses of patients with HPV-positive oropharyngeal cancer do not have increased oral HPV infections ( Dr Gypsyamber D’Souza - Johns Hopkins Bloomberg School of Public Health, Baltimore, USA )
1 Jun 2013
New MEK inhibitor selumetinib is the first effective drug for advanced melanoma ...
Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA
New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye ( Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA )
1 Jun 2013
Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients wi...
Dr Mario Sznol - Yale Cancer Center New Haven, USA
Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma ( Dr Mario Sznol - Yale Cancer Center New Haven, USA )
1 Jun 2013
Maintenance therapy with multi-targeted drug pazopanib delays relapse of advance...
Dr Andreas du Bois - Kliniken Essen Mitte, Germany
Maintenance therapy with multi-targeted drug pazopanib delays relapse of advanced ovarian cancer ( Dr Andreas du Bois - Kliniken Essen Mitte, Germany )
1 Jun 2013
Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone
Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2013